Pfizer and BioNTech announced Wednesday they will supply 200 million doses of their COVID-19 vaccine, if it’s ultimately approved, to member states in the European Union.
The companies said the deal also gives the bloc an option for another 100 million doses of their BNT162b2 vaccine, which is in the final stage of human clinical trials and awaiting regulatory approvals.
“Today’s finalized supply agreement with the European Commission represents the largest initial order of vaccine doses for Pfizer and BioNTech to date and a major step toward our shared goal of making a COVID-19 vaccine available to vulnerable populations,” Pfizer Chairman and CEO Albert Bourla said in a statement.
“This is the most promising vaccine so far,” European Commission President Ursula von der Leyen added. “Once this vaccine becomes available, our plan is to deploy it quickly, everywhere in Europe.”
